NUZ.ASX: HEALEY ALS Trial Regimen I Expands to 240 Participants

HEALEY ALS Trial Regimen I Expands to 240 Participants

Stock	NUZ.ASX (NUZ.ASX)
Release Time	27 May 2026, 9:20 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Nunziz Announces Expansion of HEALEY ALS Trial Regimen I

Key Points

Expansion of Regimen I from 160 to 240 participants
Enrollment rate exceeds original expectations
Philanthropic funds offset increased costs

Full Summary

Neurizon Therapeutics Limited, a clinical-stage biotech company, announced an expansion of Regimen I in the HEALEY ALS Platform Trial to 240 participants. The expansion is due to the enrollment rate exceeding original expectations and the absence of a concurrent regimen. The increased sample size aims to maintain statistical power and provide a more robust analysis of subgroups and biomarkers. Neurizon expects last participant dosing in Q2 CY2027, with topline results anticipated in early Q3 CY2027. The expansion is expected to have no impact on Neurizon's costs through to topline results, with only a modest increase in the total cost of completing the full trial.

Guidance

Last participant dosing expected in Q2 CY2027, topline results in early Q3 CY2027

Outlook

Neurizon expects the larger, more robust dataset to strengthen partnering and commercial positioning for NUZ-001.